PCSK9 Inhibitor, EGF-A is an inhibitor of PCSK9. It corresponds to residues 293-334 of the EGF-A domain of the low-density lipoprotein (LDL) receptor. This compound prevents PCSK9-induced intracellular degradation of LDL receptors and can be utilized in the research of hypercholesterolemia and premature atherosclerosis.
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
